Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFA-281 in healthy volunteers
NCT05547503Phase 1Completed
- Sponsor
- AfaSci, Inc.
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain comparing Placebo Control with AFA-281 (2 arms). Primary endpoints: Treatment-Related Adverse Events at 72 hours, Heart Rate at 72 hours and 10 more. Started Apr 2023; status: completed.
02
Drugs
AFA-281
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05547503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547503.